A Novel Predictor of Chemotherapeutic Cardiotoxicity in Patients with Non-Hodgkin Lymphoma

Basit Öğe Kaydı
dc.authoridÖzkan, Uğur/0000-0002-7552-7654
dc.authorwosidÖzkan, Uğur/ACR-6091-2022
dc.contributor.authorGurdogan, Muhammet
dc.contributor.authorOzkan, Ugur
dc.date.accessioned2024-06-12T10:55:32Z
dc.date.available2024-06-12T10:55:32Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: It is known that chemotherapeutic agents cause myocardial cell damage leading to left ventricular dysfunction and heart failure. Fragmented QRS is an indication of fibrosis developing as a result of myocardial cell damage. The aim of this study is to assess whether there is a relationship between the chemotherapeutic treatment and the development of the fragmented QRS complex in electrocardiography (ECG). Patients and Methods: Among 130 patients who were diagnosed with non-Hodgkin lymphoma and received an R-CHOP treatment regimen, the potential emergence of fragmented QRS on ECG as well as the changes in the left ventricular ejection fraction (LVEF) (on transthoracic echocardiography) in response to various chemotherapeutic regimens were sought. Results: New development of a fragmented QRS pattern was observed in 53 of the 130 patients (40.8%). These patients were found to have lower LVEF values along with higher numbers of chemotherapy courses and cumulative doses. In the logistic regression analysis, age (OR = 1.042; 95% CI 1.009-1.076; p = 0.012) and number of courses (OR = 1.848; 95% CI 1.409-2.423; p < 0.001) were found to be the most important predictors of fragmented QRS development. In subjects with a fragmented QRS pattern, there was a significant difference between the initial and repeat LVEF values (p < 0.001). Importantly the emergence of a fragmentation pattern occurred much earlier compared to the drop in LVEF values (10.62 +/- 4.04 vs. 15.24 +/- 7.49 months). Conclusion: Development of a fragmented QRS pattern in response to cancer therapy emerges as a new parameter potentially predictive of chemotherapy-induced cardiotoxicity.en_US
dc.identifier.doi10.1159/000500439
dc.identifier.endpage381en_US
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.issue7-8en_US
dc.identifier.pmid31132772en_US
dc.identifier.scopus2-s2.0-85067058447en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage375en_US
dc.identifier.urihttps://doi.org/10.1159/000500439
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19465
dc.identifier.volume42en_US
dc.identifier.wosWOS:000480269300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology Research And Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCancer Chemotherapyen_US
dc.subjectCardiotoxicityen_US
dc.subjectNon-Hodgkin Lymphomaen_US
dc.subjectFragmented QRSen_US
dc.subjectCardio-Oncologyen_US
dc.subjectFragmented Qrs Complexen_US
dc.subjectDoxorubicinen_US
dc.subjectFibrosisen_US
dc.subjectAdultsen_US
dc.titleA Novel Predictor of Chemotherapeutic Cardiotoxicity in Patients with Non-Hodgkin Lymphomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu